Neurometrix (NASDAQ:NURO) has received an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.
Zacks has also assigned Neurometrix an industry rank of 177 out of 255 based on the ratings given to related companies.
Separately, ValuEngine downgraded Neurometrix from a “buy” rating to a “hold” rating in a research report on Wednesday, April 18th.
Several hedge funds and other institutional investors have recently modified their holdings of NURO. Renaissance Technologies LLC grew its stake in shares of Neurometrix by 68.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,783 shares of the medical device company’s stock valued at $214,000 after buying an additional 50,200 shares in the last quarter. Sabby Management LLC grew its stake in shares of Neurometrix by 92.4% in the fourth quarter. Sabby Management LLC now owns 180,039 shares of the medical device company’s stock valued at $310,000 after buying an additional 86,478 shares in the last quarter. Finally, Thompson Davis & CO. Inc. grew its stake in shares of Neurometrix by 114.0% in the first quarter. Thompson Davis & CO. Inc. now owns 90,647 shares of the medical device company’s stock valued at $128,000 after buying an additional 48,291 shares in the last quarter. 14.67% of the stock is owned by institutional investors and hedge funds.
NASDAQ:NURO traded down $0.02 on Friday, reaching $1.23. The company’s stock had a trading volume of 100 shares, compared to its average volume of 447,662. Neurometrix has a 12-month low of $1.20 and a 12-month high of $3.18.
Neurometrix (NASDAQ:NURO) last posted its earnings results on Friday, April 20th. The medical device company reported $0.08 EPS for the quarter. Neurometrix had a negative return on equity of 161.28% and a negative net margin of 47.75%. The company had revenue of $4.94 million for the quarter.
Neurometrix Company Profile
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.